Intelligence · Clinical Pipeline
Tour Hekla Pipeline
All ClinicalTrials.gov programs at Tour Hekla — phase, modality, and trial IDs.
- Programs
- 5
Quick answer
Tour Hekla has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
CHLORURE DE SODIUM 0,9 % VIAFLO, solution pour perfusion, Avastin 25 mg/ml concentrate for solution for infusion.
Tour Hekla
1st line treatment for unresectable metastatic colorectal cancer
1 trial -
Carvedilol NORMON 6.25 mg tablets EFG., Il n'a pas de substance active. Le produit est un comprimé pelliculé sécable blanc, de forme ovale, de longueur 8mm, avec une gravure F57 sur une face et une barre de sécabilité sur l’autre face. Excipients: Prosolv Easytab SP (Cellulose microcristalline, Silice colloïdale, Sodium starch glycolate, Sodium stéaryl fumarate). Solution de pelliculage: (Hypromellose, PEG 3350, Candurin silver sheen)
Tour Hekla
Asymptomatic Child-Pugh A5 to B8 cirrhosis
1 trial -
Iohexol 300 mg I/ml solution for injection, MORPHINE (CHLORHYDRATE) RENAUDIN 1 mg/ml, solution injectable
Tour Hekla
Evaluation of the CKD-Epi score to identify a glomerular filtration threshold predictive of morphine failure at usual dosage, using a reference method for assessing renal function: iohexol clearance. All other aspects of the protocol are part of standard care practice.
1 trial -
PROPESS 10 mg, système de diffusion vaginal, PROSTINE E2 2 mg/3 g, gel vaginal, ANGUSTA 25 microgrammes, comprime, OXYTOCINE PANPHARMA 5 UI/1 ml, solution injectable
Tour Hekla
Labor Induction of women with an unfavorable Cervix after 24 hours of cervical ripening
1 trial -
RITALINE L.P. 10 mg, gélule à libération prolongée
Tour Hekla
Attention Deficit Disorder with or without Hyperactivity (ADHD) is a neurodevelopmental disorder characterized by disabling symptoms of inattention and/or hyperactivity-impulsivity beginning before the age of 12 with significant personal, social, academic and/or occupational impact (American Psychiatric Association 2013). This disorder, whose prevalence is around 5% in children and adolescents, affects 2.6% of adults (American Psychiatric Association 2013; Song et al. 2021).
1 trial
Frequently asked questions
How many pipeline programs does Tour Hekla have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs